Try our Advanced Search for more refined results
9,187,405
S1P receptor modulators for treating relasping-remitting multiple sclerosis
- October 11, 2022 Justices Asked To Keep Staying Novartis' Gilenya IP Loss
- October 05, 2022 Justices Told Gilenya Generic Stay Bid Is A Weak Cash Grab
- September 29, 2022 High Court Halts Generic Gilenya As Novartis Appeals IP Loss
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Archive of over 450,000 articles
- Database of over 2.1 million cases
- 62,000+ organization-specific pages.
- Daily and real-time news and case alerts on organizations, industries, and customized search queries.
- Significant legal events involving law firms, companies, industries, and government agencies.
- Learn more
TRY LAW360 FREE FOR SEVEN DAYS
View all the results
Already a subscriber? Click here to login